| The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases V Pillay, L Allaf, AL Wilding, JF Donoghue, NW Court, SA Greenall, ... Neoplasia 11 (5), 448-IN2, 2009 | 129 | 2009 |
| Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma SA Greenall, YC Lim, CB Mitchell, KS Ensbey, BW Stringer, AL Wilding, ... Oncogenesis 6 (5), e336-e336, 2017 | 71 | 2017 |
| EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications SA Greenall, JF Donoghue, M Van Sinderen, V Dubljevic, S Budiman, ... Oncogene 34 (41), 5277-5287, 2015 | 60 | 2015 |
| Biochemical characterization of individual human glycosylated pro-insulin-like growth factor (IGF)-II and big-IGF-II isoforms associated with cancer SA Greenall, JD Bentley, LA Pearce, JA Scoble, LG Sparrow, NA Bartone, ... Journal of Biological Chemistry 288 (1), 59-68, 2013 | 50 | 2013 |
| Glioma specific extracellular missense mutations in the first cysteine rich region of epidermal growth factor receptor (EGFR) initiate ligand independent activation SI Ymer, SA Greenall, A Cvrljevic, DX Cao, JF Donoghue, VC Epa, ... Cancers 3 (2), 2032-2049, 2011 | 46 | 2011 |
| Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET SA Greenall, E Gherardi, Z Liu, JF Donoghue, AA Vitali, Q Li, R Murphy, ... PloS one 7 (4), e34658, 2012 | 40 | 2012 |
| Effects of gefitinib, an epidermal growth factor receptor inhibitor, on human placental cell growth UW Nilsson, TG Johns, T Wilmann, T Kaitu’u-Lino, C Whitehead, ... Obstetrics & Gynecology 122 (4), 737-744, 2013 | 37 | 2013 |
| Activation of ERBB4 in glioblastoma can contribute to increased tumorigenicity and influence therapeutic response JF Donoghue, LT Kerr, NW Alexander, SA Greenall, AB Longano, ... Cancers 10 (8), 243, 2018 | 24 | 2018 |
| Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo. SA Greenall, JF Donoghue, NG Gottardo, TG Johns, TE Adams Oncogene 34 (13), 1658-1666, 2015 | 24 | 2015 |
| Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma SA Greenall, M McKenzie, E Seminova, O Dolezal, L Pearce, J Bentley, ... Neuro-oncology 21 (8), 1016-1027, 2019 | 21 | 2019 |
| EGFRvIII: the promiscuous mutation SA Greenall, TG Johns Cell Death Discovery 2 (1), 1-2, 2016 | 21 | 2016 |
| A pre-clinical assessment of the pan-ERBB inhibitor dacomitinib in pediatric and adult brain tumors R Endersby, J Whitehouse, H Hii, SA Greenall, TG Johns, NG Gottardo Neoplasia 20 (5), 432-442, 2018 | 20 | 2018 |
| Antibody fragments, expressed by a fowl adenovirus vector, are able to neutralize infectious bursal disease virus SA Greenall, SG Tyack, MA Johnson, SI Sapats Avian pathology 39 (5), 339-348, 2010 | 20 | 2010 |
| Incomplete target neutralization by the anti-cancer antibody rilotumumab SA Greenall, TE Adams, TG Johns MAbs 8 (2), 246-252, 2016 | 18 | 2016 |
| Differential sensitivity of human hepatocellular carcinoma xenografts to an IGF-II neutralizing antibody may involve activated STAT3 SA Greenall, J Donoghue, TG Johns, TE Adams Translational Oncology 11 (4), 971-978, 2018 | 5 | 2018 |
| 153. COMBINATION METHOTREXATE AND EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITION AS A NOVEL MEDICATION-BASED CURE OF ECTOPIC PREGNANCIES U Nilsson, TG Johns, T Wilmann, Y Gao, C Whitehead, E Dimitriadis, ... Reproduction, Fertility and Development 22 (9), 71-71, 2010 | 2 | 2010 |
| DDIS-19. CT-179: An Inhibitor of The Olig2 Transcription Factor with Potent Anti-Tumour Activity In Brain Cancer G Jungwirth, C Jungk, R Warta, A Unterberg Neuro-oncology, 2018 | 1 | 2018 |
| EAPH-16. discovery of CT-179: a small molecule inhibitor of the Olig2 transcription factor with potent anti-tumor in pediatric brain cancer T Johns, S Greenall, C Chen, B Day Neuro-Oncology 20 (Suppl 2), i68, 2018 | 1 | 2018 |
| Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma. M McKenzie, M Kuchibhotla, SC Chen, KL McDonald, HI Kornblum, ... Neuro-Oncology, 2020 | | 2020 |
| Most clinically approved anti-EGFR antibodies fail to neutralize EGFRvIII, leading to lack of anti-tumour efficacy in high grade glioma S Greenall, T Adams, T Johns Annals of Oncology 29, ix21, 2018 | | 2018 |
